Company Press Release

2022 Health Trends: Insights for Industry Change Agents

. From patient-powered design to accelerated integration across the product lifecycle, this year’s 

 report empowers organizations to be catalysts for change by anticipating what’s to come.

Trends for 2022 focus on new models for creating stakeholder value, the importance of prioritizing human relationships at every healthcare encounter and strengthening technology-enabled insights to speed the delivery of life-changing therapies to patients.

The top 10 trends set to catalyze the year ahead align around key themes focused on Value Creation, Human Centricity and Industry Change.

Ensuring that data and insights flow across the product lifecycle to deliver on innovation’s promise, creating greater value for all stakeholders.

Appropriate acceleration in clinical development


Acceleration will be driven by innovative study design and execution, real world data engines, flexible decentralized engagement and dynamic contracting.

New commercial models will have two key dimensions: The human and the digital. Omnichannel engagement will be used to amplify critical human interactions and deliver powerful insights on when and how to act most efficiently in all channels.

As the patient voice rises, a long-standing communications gap between patients and those who innovate on their behalf is finally beginning to close.

Prioritizing the personal relationships at the core of every healthcare interaction and strengthening them with tech-enabled insights.

Look for important disruptions in how key stakeholders engage with each other, including a newly hybrid field, changing roles for clinical research associates (CRAs), new paths to recruitment and simplification of the complex.

Engaging the burned-out healthcare professional


A profession that already faced dangerous levels of burnout has suffered even more over the last two years fighting a pandemic, lacking access to patients, a short supply of critical resources and isolation from peers. Engaging them is different now.​

In the span of a year, we went from unprecedented hiring levels across biopharma in response to the urgent need to support public safety, to many organizations being short staffed against changing business priorities.

According to a recent benchmarking study by Syneos Health, biopharma leaders on average rate their use of modern customer engagement and omnichannel infrastructure at six out of 10, notably better than prior to the pandemic. In 2022, the transformation accelerates.

Stepping up to address social policy public health issues head-on, leading by example in a newly dynamic environment for innovation.

Advancing DE&I inside biopharma organizations and among stakeholder populations will be a critical strategic priority for the industry in 2022 and beyond.

Pharmaceutical industry reputation showed an unprecedented resurgence in 2021—largely due to its rapid response to the pandemic. At the same time, trust in government institutions suffered—leaving manufacturers to fill the void by communicating with scientific rigor and transparency. Maintaining and growing the industry’s reputation will be a key opportunity for 2022.

After years of responding and reacting, biopharma is ready to take bold new steps forward, leveraging new levels of funding, new resourcing models and partners for enhancing asset value, new global centers of excellence—and even new constraints—to advance life sciences innovation.

Articles

Insights from Syneos Health’s 2022 Health Trends: Insights for Industry Change Agent.

Syneos Health 2022 Health Trends 

, an agency for eClinical teams, has provided this infographic that categorizes more than 190 companies in this space by their focus.

Bracken Marketing has provided this infographic that categorizes more than 190 companies in this space by their focus.

A Visual for the eClinical Landscape

Clinical trial costs have surged over the past decade, with recent reports stating that from 2008 to 2013, the average cost per patient increased by $23,600, or by 157%. A major contributor to the cost of a clinical trial is subject recruitment and the associated staff costs.	 	So, examining every opportunity to reduce the sample size for a study is an important and necessary step in drug development.	 	Reducing sample size without losing power can be accomplished by one of three principles. In this infographic, Statsols examines these and present 15 ways researchers can reduce sample size in clinical trials.	 	Check out the infographic 

Ways to Reduce Sample Size In Clinical Trials

	PAREXEL Advances Patient-Centric Drug Development with Introduction of its Patient Innovation Center

 – PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced the launch of its Patient Innovation Center, designed to help guide sponsors in their efforts to improve efficiency and success across all areas of biopharmaceutical development including clinical trial design, recruitment, execution and market access.  With a patient-centric approach, the Center can help sponsors improve the drug development process by reducing the practical, financial and geographical barriers patients and caregivers often face, and optimize patient involvement and engagement.

	Simplifying the patient journey with a focus on the patient’s needs and experience has been proven to enhance the drug development and commercialization process.  A 

 recently released by The Economist Intelligence Unit (EIU) and commissioned by PAREXEL found that patient-centric trials took almost half the time to recruit participants and that drugs developed using these approaches were 19 percent more likely to be launched.  However, patient-centric designs were only utilized in 5.2 percent of Phase II and III trials across the industry. In the commercialization phase, a patient-centric approach can enhance the process as well.  With the Patient Innovation Center, PAREXEL will help facilitate sponsors’ ability to develop comprehensive strategies for patient-centric drug development and commercialization and leverage new approaches including Patient-Centric 

, virtual (or at-home) trials and direct-with-patient studies.

	“While the evidence is clear that patient-centric approaches can improve the development process, many sponsors remain in need of a roadmap to effectively apply these strategies over time,” said Sy Pretorius, M.D., Senior Vice President, Medical & Scientific Services, PAREXEL.  “At PAREXEL we are committed to designing trials with patients in mind.  Through the Patient Innovation Center, we aim to bring the full breadth of our services, expertise and innovation to clients to help more-effectively implement these approaches, reducing the barriers and optimizing patient involvement throughout the drug development and commercialization journey.”
	
	PAREXEL’s Patient Innovation Center services include:

 PAREXEL’s Patient-Centric Protocol Optimization service proactively involves patients and PAREXEL Site Alliance expert nurses in the protocol-design process to identify and address potential practical challenges to study participation. By maintaining focus on patients’ needs and augmenting the feasibility process, patient burden can be reduced and the experience for participants optimized.  By using a combination of web listening, patient, caregiver and site staff input, PAREXEL can help sponsors positively impact study recruitment and retention.

: PAREXEL’s patient-centric focus can help ensure a pragmatic approach to study implementation to reduce patient burden, including the deployment of virtual trials.  It includes elements such as online recruitment, eConsent, home nursing, direct-to-patient drug shipments, patient apps and video dosing to enhance patient experience and compliance.  PAREXEL’s 

 service is focused on continuous data collection through the use of wearables to remotely capture, transmit and store data in a secure platform powered by PAREXEL’s Perceptive

 Cloud.  Deployment of the virtual trials service brings the research to patients and their caregivers, reducing the practical, financial and geographical barriers to clinical study participation for patients and their families.

: PAREXEL’s commitment to encompassing the patient’s needs and experience extends throughout the product development lifecycle – and is critically focused on ensuring patient access to important therapies.  In preparing for and supporting product commercialization, PAREXEL aims to deliver research that reflects patients’ true care path and experience – and that will ultimately support the key clinician, payer, and regulatory decisions that will drive patient access.  PAREXEL’s approach leverages technologies and processes to collect patient-specific data via mobile sensors and applications, patient-reported outcomes surveys, direct-to-patient studies and other strategies – all informed by a deep understanding of the patient care path, and the market’s clinical and payer evidence requirements.

	“In today’s drug development landscape, it is more important than ever that we as an industry place the patient’s needs at the core of everything we do,” said Peyton Howell, Chief Commercial and Strategy Officer, PAREXEL.  “At PAREXEL, we understand how critical patient involvement and engagement are to successful clinical development and, ultimately, access to therapies.  As we look to the future, we will continue to seek new ways to optimize the patient experience as we partner with our clients to develop and deliver important new medicines.”

	For more information about PAREXEL visit 


	
	PAREXEL International Corporation is a leading innovator of global biopharmaceutical services.  We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services.  PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world. For more information, visit 

	PAREXEL is a registered trademark of PAREXEL International Corporation. All other trademarks are the property of their respective owners.

Parexel Patient Centric DD PR

	Clinerion and Semicrol integrate Patient Network Explorer and Fundanet CTMS to enable end-to-end clinical trial management.
	 
	Clinerion and Semicrol announce a collaboration which will integrate the functionality of Clinerion’s Patient Network Explorer with Semicrol’s Fundanet CTMS. The partnership will integrate patient data throughout the clinical trial process, from planning to reporting of results.
	 
	The technical and commercial collaboration between the two companies will integrate the functionality of Clinerion’s Patient Network Explorer with Semicrol’s Fundanet Clinical Trials Management System (CTMS), enabling the automated, efficient sharing of patient data from a hospital’s electronic health records system to the CTMS running a clinical trial at that hospital.
	 
	The collaboration will give clinical trial sponsors and managers unified tools to manage trial data and workflows throughout the clinical trial process, from planning to reporting of results. This will enable a broader approach in clinical trials, drug development support and better outcomes for patients. Patient data privacy is preserved, and patient data remains within the hospital IT infrastructure throughout.
	 
	Fundanet CTMS is a world-class clinical trial management system designed to provide quick and easy access to study or subject information utilizing simple and intuitive navigation. Patient Network Explorer aggregates patient insights from anonymized patient records throughout Clinerion’s global network of partner hospitals to provide services for clinical trial protocol feasibility, site selection, and patient search and identification, as well as generating real-world data for medical access applications.
	 
	“We have seen a significant shift in recent years in the complexity of clinical research recruitment processes and the amount of time needed to identify eligible patients to be successful in the clinical trial enrollment,” said Vicente Alciturri, International Director of Semicrol. “In order to meet the changing needs of the research marketplace, we sought out a partner who shared the same core values as us for helping researchers conduct the best possible research and improve operations. We found that partner in Clinerion. The technology flexibility and years of experience makes Clinerion an ideal fit for Fundanet CTMS and an exciting new offering for the clinical research Institutes, CROs and pharma industry as a whole in Spain, Portugal and Latin America. This integrated solution will allow users to reduce redundancy, obtain directly access to high-quality data, and make decisions faster. We look forward to a great partnership.”
	 
	“Semicrol is one of the innovative market players in the world of software solutions for the clinical research and we are pleased to partner with them in bringing a joint offer to hospitals and trial sites,” says Ian Rentsch, CEO of Clinerion. The complementarity of Patient Network Explorer and Fundanet CTMS creates a combined service which offers more than the sum of its parts.”
	 
	Semicrol and Clinerion will present their collaboration for the first time at the BIOSPAIN Congress at Seville, Spain, on September 25th-27th, 2018.
	 
	About Clinerion
	 
	Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.
	Clinerion website: www.clinerion.com
	Clinerion’s Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer
	 
	For more information, please contact:
	Le Vin Chin
	Director, Head of Marketing and Communications
	Clinerion Ltd
	Margarethenstrasse 47, CH-4053 Basel, Switzerland
	Tel.: +41 61 865 60 54
	media@clinerion.com
	 
	About Semicrol SL
	 
	Semicrol, the creator of Fundanet CTMS, is a leader in cloud-based software solutions for the clinical research industry and is dedicated to solving problems and providing systems that make the research process more efficient and more profitable throughout the software framework.
	Fundanet CTMS is a world-class clinical trial management system designed to provide quick and easy access to study or subject information utilizing simple and intuitive navigation.
	Semicrol Headquarter is based in Santander (Spain) and has local offices in Mexico and Bogotá (Colombia) for the LATAM region. Established in 1979, Semicrol comprises around 70 people devoted to consultancy, software development, implanting and maintaining information systems and applications for Hospitals, Research Institutes, Universities, Pharma companies, CROs and medical devices companies.
	Semicrol’s website: www.semicrol.es
	Semicrol’s Fundanet Suite: www.fundanet.es
	 
	For more information, please contact:
	Vicente Alciturri Fernández
	International Director
	SEMICROL S.L.
	C/ Isabel Torres, 7, 39011 Santander, Cantabria, Spain
	Tel.: +34 942 314 224
	vicente.alciturri.fernandez@semicrol.com
	 

Company Press Release

Articles

Syneos Health 2022 Health Trends

A Visual for the eClinical Landscape

Ways to Reduce Sample Size In Clinical Trials

Ways to Reduce Sample Size In Clinical Trials

Parexel Patient Centric DD PR

Clinerion Semicrol PR